Breast cancer is a common disease that has a better prognosis when detected early. Current screening and monitoring technologies have increased survival rates, but their limits have prompted researchers to look into biomarker assessment to better early diagnosis and therapy monitoring. The enzyme-linked immunosorbent assay (ELISA) is a specific and robust technique for measuring protein biomarkers in blood or its components.
